Articles tagged "Graft arterlosclerosis"

2022 American Transplant Congress
Targeting the Bet Family Protein Brd4 Inhibits Inflammatory Macrophages and Promotes Heart Allograft Tolerance
X. Xiao
Surgery, Houston Methodist Hospital, Houston, TX
*Purpose: Infiltration of allografts by inflammatory macrophages is frequently associated with chronic graft loss In both animal models and clinical settings, but the mechanisms that…
2022 American Transplant Congress
Bcl6b is a Putative Regulator of Endothelial Identity and Endmt
N. M. Valenzuela
Pathology and Laboratory Medicine, UCLA, Los Angeles, CA
*Purpose: Loss of endothelial cell (EC) identity is central to endothelial to mesenchymal transition (EndMT) implicated in neointimal hyperplasia in transplant vasculopathy. However, the molecular…
2022 American Transplant Congress
A Sustained Injury Response by Regulatory T Cells (Treg) Contributes to Fibrosis to Promote Chronic Rejection After Heart Transplantation
J. Bou Saba¹, L. Fan¹, X. Zhang¹, T. Li¹, L. R. Mathews¹, G. Dwyer², E. Colon², M. J. Calderon³, K. E. Helfrich³, M. A. Ross³, S. C. Watkins³, H. Turnquist¹
¹Surgery, University of Pittsburgh, Thomas E. Starzl Transplantation Institute, Pittsburgh, PA, ²Immunology, University of Pittsburgh, Thomas E. Starzl Transplantation Institute, Pittsburgh, PA, ³Cell Biology, University of Pittsburgh, Center for Biologic Imaging, Pittsburgh, PA
*Purpose: Chronic rejection (CR) results from the development of immunosuppressant-resistant allograft vasculopathy and fibrosis and remains a leading cause of recipient death one-year post-heart transplant…
2022 American Transplant Congress
Improvement in Kidney Function After Early Conversion to Belatacept-Based Regimen in Allografts with Biopsy-Proven Donor Vascular Disease
T. Ommert¹, J. Javier¹, J. Jackson¹, C. Klein²
¹Piedmont Transplant Institute, Piedmont Atlanta Hospital, Atlanta, GA, ²Piedmont Transplant Institute, Atlanta, GA
*Purpose: Donor arteriosclerosis in the kidney allograft predicts poorer graft outcomes and is a risk factor for tacrolimus-induced nephrotoxicity. Belatacept conversion has been utilized as…
2021 American Transplant Congress
Findings from the Bareto Study: Associations Between Chronic Vascular Changes and 10-year Transplant Graft Outcomes
L. Kamal¹, D. Stewart², J. Foutz², H. McGehee², P. Saravanane¹, S. Yu¹, R. Yusfi¹, G. Gupta¹
¹Virginia Commonwealth University, Richmond, VA, ²UNOS, Richmond, VA
*Purpose: As part of a broader study on Biopsy, Anatomy, and Resistance Effects on Transplant Outcomes (BARETO), we aim to characterize the poorly understood relationship…
2020 American Transplant Congress
Age-Enhanced Transplant Vasculopathy Associates with Impaired Vascular Mitophagy
M. Blin¹, D. Tyrrell¹, S. Wood¹, D. Farris¹, S. G. Tullius², D. R. Goldstein¹
¹Micro and Immunology/Internal Medicine, University of Michigan, Ann Arbor, MI, ²Transplant Surgery, Brigham and Women's Hospital, Boston, MA
*Purpose: Donor aging leads to increased chronic allograft vasculopathy (CAV) for unclear reasons. Here, we investigated whether impaired alterations in mitophagy, a mechanism to remove…
2020 American Transplant Congress
Impact of Alemtuzumab Induction on Cardiac Allograft Vasculopathy in Orthotopic Heart Transplant Recipients
M. Plazak¹, X. Gao², S. Gale², B. Reed², R. Madathil¹, S. Hammad¹, B. Ravichandran¹
¹University of Maryland Medical Center, Baltimore, MD, ²University of Maryland School of Pharmacy, Baltimore, MD
*Purpose: Cardiac allograft vasculopathy (CAV) is impacted by acute rejection and ultimately limits long-term survival of orthotopic heart transplant (OHT) recipients, thus there is interest…
2020 American Transplant Congress
Impact of Statin Intensity on the Development of Cardiac Allograft Vasculopathy
K. Goehring¹, W. Kuan¹, A. Sieg¹, K. L. Dawson¹, A. R. Kolodziej²
¹Department of Pharmacy, University of Kentucky HealthCare, Lexington, KY, ²Gill Heart and Vascular Institute, University of Kentucky HealthCare, Lexington, KY
*Purpose: This study aims to examine the efficacy of high-intensity statin therapy compared to low-intensity, moderate-intensity, or no statins at preventing cardiac allograft vasculopathy (CAV)…
2020 American Transplant Congress
Taking it to the Max: Extremely Low LDL May Provide Benefit for Prevention of Cardiac Allograft Vasculopathy
R. Lee¹, E. J. Henricksen¹, Y. Moayedi², K. Y. Feng³, J. Han³, W. Yang⁴, R. Imai¹, J. J. Teuteberg⁴, K. K. Khush⁴
¹Pharmacy, Stanford Health Care, Stanford, CA, ²University Health Network, Toronto, ON, Canada, ³Medicine, Stanford University, Stanford, CA, ⁴Cardiac Transplant, Stanford University, Stanford, CA
*Purpose: Routine use of statins is the only Class I ISHLT recommendation in heart transplantation (HT) to reduce cardiac allograft vasculopathy (CAV) and improve survival.…
2020 American Transplant Congress
Regulatory T Cell-Derived Amphiregulin Activates Fibroblasts to Promote Chronic Rejection after Heart Transplantation
L. Fan¹, X. Zhang¹, T. Li¹, L. R. Mathews¹, G. K. Dwyer², M. J. Calderon³, K. E. Helfrich³, M. A. Ross³, S. C. Watkins³, H. R. Turnquist¹
¹Surgery, University of Pittsburgh, Pittsburgh, PA, ²Immunology, University of Pittsburgh, Pittsburgh, PA, ³Center for Biologic Imaging, University of Pittsburgh, Pittsburgh, PA
*Purpose: Chronic rejection (CR) after organ transplantation (Tx) manifests as function-limiting allograft fibrosis and vasculopathy. Current immunosuppressants fail to prevent CR and insights into the…